Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Oral Hexavalent Reassortant Rotavirus Live Attenuated Vaccine
NCT06950645Phase 1Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hexavalent reassortant rotavirus attenuated live vaccine in rotavirus gastroenteritis (6 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Safety of the investigational vaccine (Adverse Events). Started Mar 2024; status: completed.
02
Drugs
hexavalent reassortant rotavirus attenuated live vaccine
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT06950645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06950645.